SYNAPS Dx Joins Maryland Tech Council
A new independent study finds that Maryland has built one of the nation’s strongest life sciences industries, which directly employs more than 54,000 workers. A division of MTC, Maryland Life Sciences, recently commissioned a report from the globally recognized Milken Institute that also identifies new opportunities for the public and private sectors to enhance Maryland’s entrepreneurial ecosystem and to strengthen its workforce development strategies.
SynapsDx is excited to collaborate with the MTC to bring about valuable innovations that can save lives and improve quality of life. SynapsDx is focused on bringing diagnostic solutions to people living with Alzheimer’s disease (AD), a type of dementia that affects memory, thinking and behavior. AD accounts for 60-80% of dementia cases and is not considered a normal aspect of aging.
AD affects an estimated 5.8 million Americans age 65 and older, with projections showing that by 2050 that number will reach 12.7 million. Given the cost and complexity of diagnosing AD, researchers are striving to determine as many aspects of AD and other dementias as possible to find new treatments to prevent, halt or reverse disease progression.